SOPHIA ANTIPOLIS, France–(BUSINESS THREAD)–Regulatory news:
Median Technologies (ALMDT) (Paris:ALMDT), announces the publication date of its 2022 half-year results and its third quarter 2022 trading performance:
*Distribution after the close of trading
About Median Technologies: About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for all. We harness the power of medical imaging using the most advanced artificial intelligence technologies to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases in their early stages and provide insights into new therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and iBiopsy®, our AI-powered software as a medical device, help biopharmaceutical companies and physicians deliver new treatments and diagnose patients earlier and more precisely. This is how we are contributing to creating a healthier world.
Founded in 2002, headquartered in Sophia-Antipolis, France, with a subsidiary in the US and another in Shanghai, Median has been awarded the “Innovative Company” seal by the BPI and is listed on the Euronext Growth market (Paris ). FR0011049824– ticker: ALMDT. Median is eligible for the French capital savings plan for SMEs (PEA-PME), is part of the Enternext® PEA-PME 150 index and has received the Euronext European Rising Tech label. For more information: www.mediantechnologies.com